Cancer Program

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: analysts
  If confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics a…
  biospace · 7h ago
• Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
  Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the…
  biospace · 13h ago
• STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
  A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.
  stat · 15h ago
• Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push
  Merck & Co. and Moderna's personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival when paired with Keytruda for patients with high-risk skin cancer. The phase 3 win se…
  fiercebiotech · 1d ago
• Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
  The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.
  biospace · 1d ago
• Regeneron ends eye disease study due to antibody's safety profile
  The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…
  biospace · 1d ago
• Regeneron ends eye disease study due to antibody's safety profile
  The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…
  biospace · 1d ago
• AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
  An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.
  biopharma_dive · 2d ago
• AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
  AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
  biospace · 2d ago
• AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
  AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
  biospace · 2d ago